VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vir Biotechnology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.21+0.25 (+2.51%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
86.6%
147M of 169M shares
Institutional holders
237
33 new, 43 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
0 buys · 41 sales
Net sold $10.94M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| State Street Corporation | 9,964,151 | 5.90% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 14,826,039 | 10.80% | 13G (passive) amendment | Mar 31, 2025 |
| Robert Nelsen | 13,534,704 | 8.50% | 13D (active) amendment | Feb 27, 2026 |
| SoftBank Vision Fund (AIV M1) L.P. | 13,116,977 | 9.40% | 13G (passive) amendment | Dec 31, 2025 |
| Vanguard Portfolio Management | 11,554,377 | 6.85% | 13G (passive) amendment | Jun 30, 2026 |
| SB Investment Advisers (UK) Limited | 10,948,093 | 6.50% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VIR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,678,283 | 12.22% | $210.71M | +2,679,954 | 0.00% |
| ARCH Venture Management, LLC | 12,694,163 | 7.50% | $129.35M | −222,500 | 11.76% |
| Vanguard Portfolio Management LLC | 11,495,215 | 6.79% | $117.14M | +2,279,638 | 0.01% |
| Sb Investment Advisers (Uk) Ltd | 10,948,093 | 6.47% | $111.56M | – | 1.46% |
| State Street Corp | 9,964,151 | 5.89% | $101.53M | +2,823,057 | 0.00% |
| GSK plc | 8,550,954 | 5.05% | $87.13M | – | 14.47% |
| Vanguard Capital Management LLC | 6,388,775 | 3.78% | $65.10M | +1,006,672 | 0.00% |
| Point72 Asset Management, L.P. | 5,666,821 | 3.35% | $57.74M | +3,714,587 | 0.06% |
| Geode Capital Management, LLC | 3,348,366 | 1.98% | $34.12M | +690,523 | 0.00% |
| Dimensional Fund Advisors LP | 3,119,421 | 1.84% | $31.79M | +539,743 | 0.01% |
| ADAR1 Capital Management, LLC | 2,456,677 | 1.45% | $25.03M | −288,037 | 1.15% |
| Goldman Sachs Group Inc | 2,365,219 | 1.40% | $24.10M | −885,008 | 0.00% |
| FMR LLC | 2,318,294 | 1.37% | $23.62M | +246,446 | 0.00% |
| Morgan Stanley | 2,211,077 | 1.31% | $22.53M | −643,128 | 0.00% |
| Nuveen, LLC | 1,982,942 | 1.17% | $20.21M | +963,978 | 0.00% |
| Pictet Asset Management Holding SA | 1,953,316 | 1.15% | $19.90M | +472,488 | 0.02% |
| Boxer Capital Management, LLC | 1,866,000 | 1.10% | $19.01M | – | 1.43% |
| Northern Trust Corp | 1,432,165 | 0.85% | $14.59M | +446,730 | 0.00% |
| Hudson Bay Capital Management LP | 1,364,000 | 0.81% | $13.90M | −105,510 | 0.04% |
| GordonMD Global Investments LP | 1,353,552 | 0.80% | $13.79M | −165,000 | 6.67% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 237 | 147M | 86.6% | 33 / 93 | 77 / 43 | 22M | 16M |
| Q1 2026 | 252 | 140M | 82.8% | 69 / 118 | 41 / 30 | 52M | 15M |
| Q4 2025 | 218 | 116M | 68.5% | 33 / 66 | 79 / 26 | 19M | 11M |
| Q3 2025 | 213 | 107M | 63.5% | 28 / 60 | 82 / 26 | 6M | 10M |
| Q2 2025 | 213 | 111M | 65.9% | 23 / 82 | 61 / 42 | 24M | 6M |
| Q1 2025 | 233 | 93M | 55.1% | 53 / 74 | 70 / 26 | 15M | 10M |
| Q4 2024 | 208 | 89M | 52.5% | 42 / 68 | 70 / 29 | 12M | 10M |
| Q3 2024 | 197 | 89M | 52.4% | 22 / 77 | 67 / 38 | 23M | 7M |
| Q2 2024 | 215 | 89M | 52.7% | 34 / 74 | 73 / 25 | 10M | 15M |
| Q1 2024 | 209 | 94M | 55.8% | 31 / 72 | 67 / 27 | 10M | 6M |
| Q4 2023 | 206 | 91M | 53.5% | 28 / 68 | 74 / 33 | 11M | 9M |
| Q3 2023 | 214 | 89M | 52.3% | 40 / 96 | 52 / 52 | 15M | 17M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of VIR | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 7,317,395 | 4.32% | $74.56M | 0.07% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 4,945,485 | 2.92% | $50.39M | 0.47% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,846,948 | 2.86% | $49.39M | 0.00% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,476,669 | 2.05% | $35.43M | 0.02% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,155,076 | 1.86% | $32.15M | 0.04% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,996,625 | 1.18% | $20.35M | 0.04% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 1,762,412 | 1.04% | $17.96M | 0.15% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,398,483 | 0.83% | $14.25M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,343,751 | 0.79% | $11.64M | 0.03% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 1,150,997 | 0.68% | $11.73M | 0.08% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 1,114,301 | 0.66% | $11.35M | 0.07% | Jun 30, 2026 |
| iShares Biotechnology ETF | 949,158 | 0.56% | $9.67M | 0.11% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 892,320 | 0.53% | $7.73M | 0.19% | Jul 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 868,792 | 0.51% | $8.85M | 0.28% | Jun 30, 2026 |
| Vanguard Tax-Managed Small-Cap Fund | 677,373 | 0.40% | $6.90M | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Backer Marianne De | President and CEO, Director | 1,001,263 | 0.59% | Apr 30, 2026 |
| Brent Sabatini | SVP, Chief Accounting Officer | 61,902 | 0.04% | Jun 2, 2026 |
| Jason O'Byrne | EVP & Chief Financial Officer | 162,615 | 0.10% | Mar 23, 2026 |
| Mark Eisner | EVP and Chief Medical Officer | 154,024 | 0.09% | Feb 26, 2026 |
| Verneuil Vanina de | EVP, General Counsel, Corp Sec | 112,982 | 0.07% | Feb 26, 2026 |
| Ann M. Hanly | EVP & Chief Technology Officer | 117,913 | 0.07% | Feb 25, 2025 |
| Robert J. More | Director | 558,573 | 0.33% | Aug 12, 2026 |
| Timothy Coughlin | Director | 0 | – | Jun 10, 2026 |
| Janet Napolitano | Director | 21,216 | 0.01% | Jun 2, 2026 |
| Charles Elliott Sigal | Director | 49,806 | 0.03% | May 28, 2026 |
| Norbert W. Bischofberger | Director | 32,000 | 0.02% | May 28, 2026 |
| Jeffrey S. Hatfield | Director | 39,806 | 0.02% | May 28, 2026 |
| Ramy Farid | Director | 32,000 | 0.02% | May 28, 2026 |
| Vicki L. Sato | Director | 1,078,391 | 0.64% | May 4, 2026 |
| Saira Ramasastry | Director | 22,619 | 0.01% | Jun 2, 2025 |
| George A. Scangos | Director | 1,849,969 | 1.09% | Feb 25, 2025 |
| Vision Fund (Aiv M1) L.P. Softbank | 10% owner | 13,920,778 | 8.23% | Dec 3, 2025 |
| Investment Advisers (Uk) Ltd Sb | 10% owner | 14,598,536 | 8.63% | Dec 3, 2025 |
| Endurance (Cayman) Ltd SVF | 10% owner | 13,728,924 | 8.11% | Dec 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert J. More Director | Aug 11, 2026 | Other | −8,000 | – | – | 40,656 |
| Robert J. More Director | Aug 11, 2026 | Other | +8,000 | – | – | 517,917 |
| Timothy Coughlin Director | Jun 9, 2026 | Award | +8,000 | – | – | 8,000 |
| Timothy Coughlin Director | Jun 9, 2026 | Award | +8,000 | – | – | 16,000 |
| Brent Sabatini SVP, Chief Accounting Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −379 | $9.45 | $3.58K | 61,902 |
| Janet Napolitano Director | Jun 1, 2026 | Sale(10b5-1 plan) | −3,200 | $9.45 | $30.24K | 21,216 |
| Jeffrey S. Hatfield Director | May 27, 2026 | Award | +8,000 | – | – | 39,806 |
| Ramy Farid Director | May 27, 2026 | Award | +8,000 | – | – | 32,000 |
| Charles Elliott Sigal Director | May 27, 2026 | Award | +8,000 | – | – | 39,806 |
| Janet Napolitano Director | May 27, 2026 | Award | +8,000 | – | – | 24,416 |
| Robert J. More Director | May 27, 2026 | Award | +8,000 | – | – | 48,656 |
| Norbert W. Bischofberger Director | May 27, 2026 | Award | +8,000 | – | – | 21,333 |
| Vicki L. Sato Director | May 1, 2026 | Sale(10b5-1 plan) | −22,000 | $10.05 | $221.10K | 1,078,391 |
| Backer Marianne De President and CEO, Director | Apr 29, 2026 | Other | +233,532 | – | – | 286,650 |
| Backer Marianne De President and CEO, Director | Apr 29, 2026 | Other | −233,532 | – | – | 714,613 |
| Backer Marianne De President and CEO, Director | Apr 6, 2026 | Sale(10b5-1 plan) | −72,559 | $9.16 | $664.64K | 948,145 |
| Vicki L. Sato Director | Apr 1, 2026 | Sale(10b5-1 plan) | −22,000 | $9.07 | $199.54K | 1,100,391 |
| Brent Sabatini SVP, Chief Accounting Officer | Mar 23, 2026 | Sale(10b5-1 plan) | −7,711 | $9.12 | $70.32K | 61,902 |
| Jason O'Byrne EVP & Chief Financial Officer | Mar 20, 2026 | Other | +2,500 | – | – | 2,500 |
| Jason O'Byrne EVP & Chief Financial Officer | Mar 20, 2026 | Other | −2,500 | – | – | 160,115 |
| Vicki L. Sato Director | Mar 2, 2026 | Sale(10b5-1 plan) | −21,800 | $9.50 | $207.10K | 1,122,591 |
| Vicki L. Sato Director | Mar 2, 2026 | Sale(10b5-1 plan) | −200 | $9.98 | $2.00K | 1,122,391 |
| Mark Eisner EVP and Chief Medical Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −1,889 | $9.82 | $18.55K | 154,024 |
| Verneuil Vanina de EVP, General Counsel, Corp Sec | Feb 25, 2026 | Sale(10b5-1 plan) | −13,700 | $9.82 | $134.53K | 112,982 |
| Mark Eisner EVP and Chief Medical Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −1,616 | $9.53 | $15.40K | 155,913 |
| Verneuil Vanina de EVP, General Counsel, Corp Sec | Feb 24, 2026 | Sale(10b5-1 plan) | −3,117 | $9.53 | $29.71K | 126,682 |
| Jason O'Byrne EVP & Chief Financial Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −1,634 | $9.53 | $15.57K | 162,615 |
| Backer Marianne De Chief Executive Officer, Director | Feb 24, 2026 | Sale(10b5-1 plan) | −14,762 | $9.53 | $140.68K | 1,020,704 |
| Brent Sabatini SVP, Chief Accounting Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −1,430 | $9.53 | $13.63K | 69,613 |
| Vicki L. Sato Director | Feb 24, 2026 | Sale(10b5-1 plan) | −200 | $10.26 | $2.05K | 1,144,391 |
| Vicki L. Sato Director | Feb 24, 2026 | Sale(10b5-1 plan) | −42,177 | $9.75 | $411.23K | 1,144,591 |
| Vicki L. Sato Director | Feb 24, 2026 | Option exercise | +42,377 | $1.49 | $63.14K | 1,186,768 |
| Mark Eisner EVP and Chief Medical Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −2,089 | $7.45 | $15.56K | 157,529 |
| Jason O'Byrne EVP & Chief Financial Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −2,089 | $7.45 | $15.56K | 164,249 |
| Brent Sabatini SVP, Chief Accounting Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −1,829 | $7.45 | $13.63K | 71,043 |
| Verneuil Vanina de EVP, General Counsel, Corp Sec | Feb 23, 2026 | Sale(10b5-1 plan) | −4,445 | $7.45 | $33.12K | 129,799 |
| Backer Marianne De Chief Executive Officer, Director | Feb 23, 2026 | Sale(10b5-1 plan) | −19,039 | $7.45 | $141.84K | 1,035,466 |
| Mark Eisner EVP and Chief Medical Officer | Feb 22, 2026 | Award | +55,000 | – | – | 159,618 |
| Jason O'Byrne EVP & Chief Financial Officer | Feb 22, 2026 | Award | +55,000 | – | – | 166,338 |
| Brent Sabatini SVP, Chief Accounting Officer | Feb 22, 2026 | Award | +25,000 | – | – | 72,872 |
| Verneuil Vanina de EVP, General Counsel, Corp Sec | Feb 22, 2026 | Award | +55,000 | – | – | 134,244 |
| Backer Marianne De Chief Executive Officer, Director | Feb 22, 2026 | Award | +285,000 | – | – | 1,054,505 |
| Brent Sabatini SVP, Chief Accounting Officer | Feb 13, 2026 | Sale(10b5-1 plan) | −1,530 | $7.79 | $11.92K | 47,872 |
| Vicki L. Sato Director | Feb 2, 2026 | Sale(10b5-1 plan) | −22,000 | $7.71 | $169.62K | 1,144,391 |
| Vicki L. Sato Director | Jan 2, 2026 | Sale(10b5-1 plan) | −22,000 | $5.93 | $130.46K | 1,166,391 |
| Endurance (Cayman) Ltd SVF 10% owner | Dec 1, 2025 | Sale(10b5-1 plan) | −191,854 | $5.98 | $1.15M | 13,728,924 |
| Vicki L. Sato Director | Dec 1, 2025 | Sale(10b5-1 plan) | −22,000 | $6.00 | $132.00K | 1,188,391 |
| Vision Fund (Aiv M1) L.P. Softbank 10% owner | Nov 28, 2025 | Sale(10b5-1 plan) | −61,493 | $6.44 | $396.01K | 13,920,778 |
| Vision Fund (Aiv M1) L.P. Softbank 10% owner | Nov 26, 2025 | Sale(10b5-1 plan) | −127,938 | $6.39 | $817.52K | 13,982,271 |
| Endurance (Cayman) Ltd SVF 10% owner | Nov 25, 2025 | Sale(10b5-1 plan) | −235,971 | $6.38 | $1.51M | 14,110,209 |
| Endurance (Cayman) Ltd SVF 10% owner | Nov 24, 2025 | Sale(10b5-1 plan) | −227,803 | $6.15 | $1.40M | 14,346,180 |
| Jason O'Byrne EVP & Chief Financial Officer | Nov 17, 2025 | Sale(10b5-1 plan) | −6,799 | $5.56 | $37.80K | 110,701 |
| Verneuil Vanina de EVP, General Counsel, Corp Sec | Nov 5, 2025 | Sale(10b5-1 plan) | −2,385 | $5.16 | $12.31K | 78,210 |
| Vicki L. Sato Director | Nov 3, 2025 | Sale(10b5-1 plan) | −22,000 | $5.64 | $124.08K | 1,210,391 |
| Verneuil Vanina de EVP and General Counsel | Nov 3, 2025 | Sale(10b5-1 plan) | −1,365 | $5.86 | $8.00K | 80,595 |
| Endurance (Cayman) Ltd SVF 10% owner | Oct 29, 2025 | Sale(10b5-1 plan) | −100 | $6.49 | $649 | 14,573,983 |
| Endurance (Cayman) Ltd SVF 10% owner | Oct 28, 2025 | Sale(10b5-1 plan) | −24,453 | $6.50 | $158.94K | 14,574,083 |
| Investment Advisers (Uk) Ltd Sb 10% owner | Oct 27, 2025 | Sale(10b5-1 plan) | −66,403 | $6.05 | $401.74K | 14,598,536 |
| Investment Advisers (Uk) Ltd Sb 10% owner | Oct 24, 2025 | Sale(10b5-1 plan) | −46,696 | $5.96 | $278.31K | 14,664,939 |
| Investment Advisers (Uk) Ltd Sb 10% owner | Oct 23, 2025 | Sale(10b5-1 plan) | −154,383 | $5.99 | $924.75K | 14,711,635 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jason O'Byrne Former Officer | Sep 17, 2026 | 19,357 | $212.93K | Sep 17, 2026 | Restricted Stock Vesting |
| Jason O'Byrne Former Officer | Sep 9, 2026 | 28,333 | $315.24K | Sep 9, 2026 | Stock Option Exercise |
| Jason O'Byrne Former Officer | Aug 25, 2026 | 23,148 | $242.59K | Aug 25, 2026 | Stock Option Exercise |
| Jason O'Byrne Former Officer | Aug 24, 2026 | 14,352 | $142.12K | Aug 24, 2026 | Stock Option Exercise |
| Jason O'Byrne Former Officer | Aug 21, 2026 | 25,000 | $245.30K | Aug 21, 2026 | Stock Option Exercise |
| Saira Ramasastry Former Director | Jun 29, 2026 | 16,000 | $165.14K | Jun 29, 2026 | Stock Option Exercise |
| Janet Napolitano Director | Jun 1, 2026 | 3,200 | $30.24K | Jun 1, 2026 | Restricted Stock Vesting |
| Brent Sabatini Officer | Jun 1, 2026 | 379 | $3.58K | Jun 1, 2026 | ESPP Purchase |
| Mark Eisner Former Officer | Apr 30, 2026 | 88,958 | $916.27K | Apr 30, 2026 | Option Granted - 07/15/2024 |
| Backer Marianne De Officer, Director | Apr 6, 2026 | 72,559 | $664.34K | Apr 6, 2026 | Restricted Stock Vesting |
| Brent Sabatini Officer | Mar 23, 2026 | 7,711 | $70.32K | Mar 23, 2026 | Restricted Stock Vesting |
| Lee Sato Vicki Director | Mar 2, 2026 | 88,000 | $799.92K | Mar 2, 2026 | Pre-IPO Shares |
| Mark Eisner Officer | Feb 25, 2026 | 1,889 | $18.55K | Feb 25, 2026 | Restricted Stock Vesting |
| Verneuil Vanina de Officer | Feb 25, 2026 | 13,700 | $134.53K | Feb 25, 2026 | Restricted Stock Vesting |
| Endurance (Cayman) Limited SVF Stockholder | Feb 25, 2026 | 400,000 | $3.80M | Feb 25, 2026 | Purchased in Issuer's initial public offering |